Role of metabolism in neurodegenerative disorders

Metabolism: Clinical and Experimental

Volumn 65, Issue 9, 2016, Pages 1376-1390

  Procaccini, Claudio ^a   Santopaolo, Marianna ^a   Faicchia, Deriggio ^a   Colamatteo, Alessandra ^b,c   Formisano, Luigi ^d   De Candia, Paola ^e   Galgani, Mario ^a   De Rosa, Veronica ^a,b   Matarese, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d UNIVERSITY OF SANNIO   (Italy)

^e IRCCS MULTIMEDICA   (Italy)

Author keywords

Alzheimer's disease; Huntington's diseases; Metabolism; Multiple sclerosis; Parkinson's disease

Indexed keywords

GHRELIN; INSULIN; LEPTIN; SOMATOMEDIN; HORMONE;

ALZHEIMER DISEASE; ARTICLE; CELL SURVIVAL; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; ENERGY METABOLISM; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; MULTIPLE SCLEROSIS; NERVE CELL; NONHUMAN; OBESITY; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; GENETICS; METABOLISM; SIGNAL TRANSDUCTION;

ENERGY METABOLISM; HORMONES; HUMANS; NEURODEGENERATIVE DISEASES; RECEPTOR CROSS-TALK;

EID: 84975231228     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2016.05.018     Document Type: Review

References (206)

1. G Alves, EB Forsaa, KF Pedersen, M Dreetz Gjerstad, and JP Larsen Epidemiology of Parkinson's disease J Neurol 255 2008 18 32
2. XP Wang, and HL Ding Alzheimer's disease: Epidemiology, genetics, and beyond Neurosci Bull 24 2008 105 109
3. ES Rosenzweig, and CA Barnes Impact of aging on hippocampal function: Plasticity, network dynamics, and cognition Prog Neurobiol 69 2003 143 179
4. WHO Obesity and Overweight: Fact Sheet No 311 2013 WHO
5. JB Dixon The effect of obesity on health outcomes Mol Cell Endocrinol 316 2010 104 108
6. RD Abbott, GW Ross, LR White, JS Nelson, KH Masaki, CM Tanner, and et al. Midlife adiposity and the future risk of Parkinson's disease Neurology 59 2002 1051 1057
7. LB Hassing, AK Dahl, V Thorvaldsson, S Berg, M Gatz, NL Pedersen, and et al. Overweight in midlife and risk of dementia: A 40-year follow-up study Int J Obes 33 2009 893 898
8. M Kivipelto, T Ngandu, L Fratiglioni, M Viitanen, I Kåreholt, B Winblad, and et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease Arch Neurol 62 2005 1556 1560
9. WL Xu, AR Atti, M Gatz, NL Pedersen, B Johansson, and L Fratiglioni Midlife overweight and obesity increase late-life dementia risk: A population-based twin study Neurology 76 2011 1568 1574
10. MA Ward, CM Carlsson, MA Trivedi, MA Sager, and SC Johnson The effect of body mass index on global brain volume in middle-aged adults: A cross sectional study BMC Neurol 5 2005 23
11. N Pannacciulli, A Del Parigi, K Chen, DS Le, EM Reiman, and PA Tataranni Brain abnormalities in human obesity: A voxel-based morphometric study NeuroImage 31 2006 1419 1425
12. PA Wolf, A Beiser, MF Elias, R Au, RS Vasan, and S Seshadri Relation of obesity to cognitive function: Importance of central obesity and synergistic influence of concomitant hypertension. The Framingham Heart study Curr Alzheimer Res 4 2007 111 116
13. VM Lee, M Goedert, and JQ Trojanowski Neurodegenerative tauopathies Annu Rev Neurosci 24 2011 1121 1159
14. B Kuhla, C Haase, K Flach, HJ Luth, T Arendt, and G Munch Effect of pseudophosphorylation and cross-linking by lipid peroxidation and advanced glycation end product precursors on tau aggregation and filament formation J Biol Chem 282 2007 6984 6991
15. 2 + imaging implicates Aβ 1-42 amyloid pores in Alzheimer's disease pathology J Cell Biol 195 2011 515 524
16. M Shoji, TE Golde, J Ghiso, TT Cheung, S Estus, LM Shaffer, and et al. Production of the Alzheimer amyloid beta protein by normal proteolytic processing Science 258 1992 126 129
17. A Matsumoto, and Y Fujiwara Aberrant proteolysis of the beta-amyloid precursor protein in familial Alzheimer's disease lymphoblastoid cells Eur J Biochem 217 1993 21 27
18. P Cras, M Kawai, D Lowery, P Gonzalez-DeWhitt, B Greenberg, and G Perry Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein Proc Natl Acad Sci U S A 88 1991 7552 7556
19. GS Watson, BA Cholerton, MA Reger, LD Baker, SR Plymate, S Asthana, and et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study Am J Geriatr Psychiatry 13 2005 950 958
20. E Oster, ER Dorsey, J Bausch, A Shinaman, E Kayson, D Oakes, and et al. Fear of health insurance loss among individuals at risk for Huntington disease Am J Med Genet 146A 2008 2070 2077
21. RA Whitmer, EP Gunderson, E Barrett-Connor, CP Quesenberry Jr., and K Yaffe Obesity in middle age and future risk of dementia: A 27 year longitudinal population based study BMJ 330 2005 1360
22. H Cai, WN Cong, S Ji, S Rothman, S Maudsley, and B Martin Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders Curr Alzheimer Res 9 2012 5 17
23. A Ott, RP Stolk, F van Harskamp, HA Pols, A Hofman, and MM Breteler Diabetes mellitus and the risk of dementia: The Rotterdam study Neurology 53 1999 1937 1942
24. B Kim, C Backus, S Oh, JM Hayes, and EL Feldman Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes Endocrinology 150 2009 5294 5301
25. EM Schrijvers, JC Witteman, EJ Sijbrands, A Hofman, PJ Koudstaal, and MM Breteler Insulin metabolism and the risk of Alzheimer disease: The Rotterdam study Neurology 75 2010 1982 1987
26. E Steen, BM Terry, EJ Rivera, JL Cannon, TR Neely, R Tavares, and et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 7 2005 63 80
27. K Talbot, HY Wang, H Kazi, LY Han, KP Bakshi, A Stucky, and et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline J Clin Invest 122 2012 1316 1338
28. C Carvalho, S Cardoso, SC Correia, RX Santos, MS Santos, I Baldeiras, and et al. Metabolic alterations induced by sucrose intake and Alzheimer's disease promote similar brain mitochondrial abnormalities Diabetes 61 2012 1234 1242
29. C Carvalho, N Machado, PC Mota, SC Correia, S Cardoso, RX Santos, and et al. Type 2 diabetic and Alzheimer's disease mice present similar behavioral, cognitive, and vascular anomalies J Alzheimers Dis 35 2013 623 635
30. L Ho, W Qin, PN Pompl, Z Xiang, J Wang, Z Zhao, and et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease FASEB J 18 2004 902 904
31. TR Bomfim, L Forny-Germano, LB Sathler, J Brito-Moreira, JC Houzel, H Decker, and et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers J Clin Invest 122 2012 1339 1353
32. F Bassil, PO Fernagut, E Bezard, and WG Meissner Insulin, IGF-1 and GLP-1signaling in neurodegenerative disorders: Targets for disease modification? Prog Neurobiol 118 2014 1 18
33. I Aviles-Olmos, P Limousin, A Lees, and T Foltynie Parkinson's disease, insulin resistance and novel agents of neuroprotection Brain 136 2013 374 384
34. L Blonde, and D Russell-Jones The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: An overview of the LEAD 1-5 studies Diabetes Obes Metab 11 2009 26 34
35. MJ During, L Cao, DS Zuzga, JS Francis, HL Fitzsimons, X Jiao, and et al. Glucagon-like peptide- 1 receptor is involved in learning and neuroprotection Nat Med 9 2003 1173 1179
36. T Perry, and NH Greig The glucagon-like peptides: A double-edged therapeutic sword? Trends Pharmacol Sci 24 2003 377 383
37. Z Qin, Z Sun, J Huang, Y Hu, Z Wu, and B Mei Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide Neurosci Lett 444 2008 217 221
38. I Aviles-Olmos, J Dickson, Z Kefalopoulou, A Djamshidian, P Ell, T Soderlund, and et al. Exenatide and the treatment of patients with Parkinson's disease J Clin Invest 123 2013 2730 2736
39. Y Li, KB Duffy, MA Ottinger, B Ray, JA Bailey, HW Holloway, and et al. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease J Alzheimers Dis 19 2010 1205 1219
40. AS Buchman, RS Wilson, JL Bienias, RC Shah, DA Evans, and DA Bennett Change in body mass index and risk of incident Alzheimer disease Neurology 65 2005 892 897
41. H White, C Pieper, K Schmader, and G Fillenbaum Weight change in Alzheimer's disease J Am Geriatr Soc 44 1996 265 272
42. E Jéquier Leptin signaling, adiposity, and energy balance Ann N Y Acad Sci 967 2002 379 388
43. D Amantea, C Tassorelli, R Russo, F Petrelli, LA Morrone, G Bagetta, and et al. Neuroprotection by leptin in a rat model of permanent cerebral ischemia: Effects on STAT3 phosphorylation in discrete cells of the brain Cell Death Dis 2 2011 e238
44. W Lieb, AS Beiser, RS Vasan, ZS Tan, R Au, TB Harris, and et al. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging JAMA 302 2009 2565 2572
45. B Bigalke, B Schreitmuller, K Sopova, A Paul, E Stransky, M Gawaz, and et al. Adipocytokines and CD34 progenitor cells in Alzheimer's disease PLoS One 6 2011 e20286
46. DC Fewlass, K Noboa, FX Pi-Sunyer, JM Johnston, SD Yan, and N Tezapsidis Obesity-related leptin regulates Alzheimer's a beta FASEB J 18 2004 1870 1878
47. SJ Greco, S Sarkar, JM Johnston, and N Tezapsidis Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells Biochem Biophys Res Commun 380 2009 98 104
48. SJ Greco, KJ Bryan, S Sarkar, X Zhu, MA Smith, JW Ashford, and et al. Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease J Alzheimers Dis 19 2010 1155 1167
49. DJ Bonda, JG Stone, SL Torres, SL Siedlak, G Perry, R Kryscio, and et al. Dysregulation of leptin signaling in Alzheimer disease: Evidence for neuronal leptin resistance J Neurochem 128 2014 162 172
50. JA Matochik, ED London, BO Yildiz, M Ozata, S Caglayan, AM DePaoli, and et al. Effect of leptin replacement on brain structure in genetically leptin deficient adults J Clin Endocrinol Metab 90 2005 2851 2854
51. M Moon, JG Choi, DW Nam, HS Hong, YJ Choi, MS Oh, and et al. Ghrelin ameliorates cognitive dysfunction and neurodegeneration in intra hippocampal amyloid-β-1-42 oligomer injected mice J Alzheimers Dis 23 2011 147 159
52. H Chung, E Kim, DH Lee, S Seo, S Ju, D Lee, and et al. Ghrelin inhibits apoptosis in hypothalamic neuronal cells during oxygen-glucose deprivation Endocrinology 148 2007 148 159
53. S Gomes, I Martins, AC Fonseca, CR Oliveira, R Resende, and CM Pereira Protective effect of leptin and ghrelin against toxicity induced by amyloid-βoligomers in a hypothalamic cell line J Neuroendocrinol 26 2014 176 185
54. VP Carlini, MM Varas, AB Cragnolini, HB Schiöth, TN Scimonelli, and SR de Barioglio Differential role of the hippocampus, amygdala, and dorsal raphe nucleus in regulating feeding, memory, and anxiety-like behavioral responses to ghrelin Biochem Biophys Res Commun 313 2004 635 641
55. AE Rigamonti, AI Pincelli, B Corrà, R Viarengo, SM Bonomo, D Galimberti, and et al. Plasma ghrelin concentrations in elderly subjects: Comparison with anorexic and obese patients J Endocrinol 175 2002 R1 R5
56. S Levi, M Cox, M Lugon, M Hodkinson, and A Tomkins Increased energy expenditure in Parkinson's disease BMJ 301 1990 1256 1257
57. TR Castañeda, J Tong, R Datta, M Culler, and MH Tschöp Ghrelin in the regulation of body weight and metabolism Front Neuroendocrinol 31 2010 44 60
58. EB Kang, and JY Cho Effect of treadmill exercise on PI3K/AKT/mTOR, autophagy, and tau hyperphosphorylation in the cerebral cortex of NSE/htau23 transgenic mice J Exerc Nutr Biochem 19 2015 199 209
59. Z Tang, E Ioja, E Bereczki, K Hultenby, C Li, Z Guan, and et al. mTor mediates tau localization and secretion: Implication for Alzheimer's disease Biochim Biophys Acta 2015 1853 1646 1657
60. SC Yates, A Zafar, P Hubbard, S Nagy, S Durant, R Bicknell, and et al. Dysfunction of the mTOR pathway is a riskfactor for Alzheimer's disease Acta Neuropathol Commun 8 2013 1 3
61. S Fan, B Zhang, P Luan, B Gu, Q Wan, X Huang, and et al. PI3K/AKT/mTOR/p70S6K pathway is involved in Aβ25-35-induced autophagy Biomed Res Int 2015 2015 161020
62. A Tramutola, JC Triplett, F Di Domenico, DM Niedowicz, MP Murphy, R Coccia, and et al. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): Analysis of brain from subjects with pre clinical AD, amnestic mild cognitive impairment and late-stage AD J Neurochem 133 2015 739 749
63. F Pickford, E Masliah, M Britschgi, K Lucin, R Narasimhan, PA Jaeger, and et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice J Clin Invest 118 2008 2190 2199
64. R González-Domínguez, T García-Barrera, J Vitorica, and JL Gómez-Ariza Metabolomics reveals significant impairments in the immune system of the app/ps1 transgenic mice of alzheimer's disease Electrophoresis 36 2015 577 587
65. NP Rocha, PL Scalzo, IG Barbosa, MS de Sousa, IB Morato, EL Vieira, and et al. Circulating levels of adipokines in Parkinson's disease J Neurol Sci 339 2014 64 68
66. CA Davie A review of Parkinson's disease Br Med Bull 86 2008 109 127
67. H Bernheimer, W Birkmayer, O Hornykiewicz, K Jellinger, and F Seitelberger Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations J Neurol Sci 20 1973 415 455
68. M Mogi, A Togari, T Kondo, Y Mizuno, O Komure, S Kuno, and et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease Neurosci Lett 270 1999 45 48
69. ZC Baquet, PC Bickford, and KR Jones Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta J Neurosci 25 2005 6251 6259
70. NA Aziz, MA van der Marck, H Pijl, MG OldeRikkert, BR Bloem, and RA Roos Weight loss in neurodegenerative disorders J Neurol 255 2008 1872 1880
71. A Antonini, P Barone, R Marconi, L Morgante, S Zappulla, FE Pontieri, and et al. The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life J Neurol 259 2012 2621 2631
72. SR Kim, HY So, E Choi, JH Kang, HY Kim, and SJ Chung Influencing effect of non-motor symptom clusters on quality of life in Parkinson's disease J Neurol Sci 347 2014 310 315
73. I Amigo, and AJ Kowaltowski Dietary restriction in cerebral bioenergetics and redox state Redox Biol 2 2014 296 304
74. MG Spillantini, ML Schmidt, VM Lee, JQ Trojanowski, R Jakes, and M Goedert Alpha-synuclein in Lewy bodies Nature 388 1997 839 840
75. L Wang, YQ Zhai, LL Xu, C Qiao, XL Sun, JH Ding, and et al. Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice Exp Neurol 251 2014 22 29
76. I Moroo, T Yamada, H Makino, I Tooyama, PL McGeer, EG McGeer, and et al. Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease Acta Neuropathol 87 1994 343 348
77. HM Gao, PT Kotzbauer, K Uryu, S Leight, JQ Trojanowski, and VM Lee Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration J Neurosci 28 2008 7687 7698
78. BE Levin Glucose-regulated dopamine release from substantia nigra neurons Brain Res 874 2000 158 164
79. JA Santiago, and JA Potashkin Shared dysregulated pathways lead to Parkinson's disease and diabetes Trends Mol Med 19 2013 176 186
80. J Godau, M Herfurth, B Kattner, T Gasser, and D Berg Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease J Neurol Neurosurg Psychiatry 81 2010 536 538
81. F Mashayekhi, E Mirzajani, M Naji, and M Azari Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson's disease J Clin Neurosci 17 2010 623 627
82. M Picillo, R Erro, G Santangelo, R Pivonello, K Longo, C Pivonello, and et al. Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease J Neurol 260 2013 1724 1730
83. A Taguchi, LM Wartschow, and MF White Brain IRS2 signaling coordinates life span and nutrient homeostasis Science 317 2007 369 372
84. JL Trejo, E Carro, E Garcia-Galloway, and I Torres-Aleman Role of insulin-like growth factor I signaling in neurodegenerative diseases J Mol Med 82 2004 156 162
85. D Offen, B Shtaif, D Hadad, A Weizman, E Melamed, and I Gil-Ad Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: Possible implications for Parkinson's disease Neurosci Lett 316 2001 129 132
86. X Sun, L Huang, M Zhang, S Sun, and Y Wu Insulin like growth factor-1 prevents 1-mentyl-4-phenylphyridinium-induced apoptosis in PC12 cells through activation of glycogen synthase kinase-3beta Toxicology 271 2010 5 12
87. WM Zawada, DL Kirschman, JJ Cohen, KA Heidenreich, and CR Freed Growth factors rescue embryonic dopamine neurons from programmed cell death Exp Neurol 140 1996 60 67
88. AD Ebert, AJ Beres, AE Barber, and CN Svendsen Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease Exp Neurol 209 2008 213 223
89. R Krishnamurthi, S Stott, M Maingay, RL Faull, D McCarthy, P Gluckman, and et al. N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats Neuroreport 15 2004 1601 1604
90. A Quesada, BY Lee, and PE Micevych PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease Dev Neurobiol 68 2008 632 644
91. R Sandyk The relationship between diabetes mellitus and Parkinson's disease Int J Neurosci 69 1993 125 130
92. DP Figlewicz, MD Brot, AL McCall, and P Szot Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: A molecular study Brain Res 736 1996 54 60
93. DP Figlewicz, SB Evans, J Murphy, M Hoen, and DG Baskin Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat Brain Res 964 2003 107 115
94. RD Abbott, GW Ross, LR White, WT Sanderson, CM Burchfiel, M Kashon, and et al. Environmental, life-style, and physical precursors of clinical Parkinson's disease: Recent findings from the Honolulu-Asia aging study J Neurol 250 Suppl. 3 2003 III30 III39
95. H Chen, SM Zhang, MA Hernan, WC Willett, and A Ascherio Weight loss in Parkinson's disease Ann Neurol 53 2003 676 679
96. VG Evidente, JN Caviness, CH Adler, KA Gwinn-Hardy, and RE Pratley Serum leptin concentrations and satiety in Parkinson's disease patients with and without weight loss Mov Disord 16 2001 924 927
97. J Lu, CS Park, SK Lee, DW Shin, and JH Kang Leptin inhibits 1-methyl-4-phenylpyridinium-induced cell death in SH-SY5Y cells Neurosci Lett 407 2006 240 243
98. Z Weng, AP Signore, Y Gao, S Wang, F Zhang, T Hastings, and et al. Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling J Biol Chem 282 2007 34479 34491
99. MB Spina, SP Squinto, J Miller, RM Lindsay, and C Hyman Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system J Neurochem 59 1992 99 106
100. PW Ho, HF Liu, JW Ho, WY Zhang, AC Chu, KH Kwok, and et al. Mitochondrial uncoupling protein-2 (UCP2) mediates leptin protection against MPP + toxicity in neuronal cells Neurotox Res 17 2010 332 343
101. ZB Andrews, B Horvath, CJ Barnstable, J Elsworth, L Yang, MF Beal, and et al. Uncoupling protein-2 is critical for nigral dopamine cell survival in a mouse model of Parkinson's disease J Neurosci 25 2005 184 191
102. ZB Andrews, D Erion, R Beiler, ZW Liu, A Abizaid, J Zigman, and et al. Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism J Neurosci 29 2009 14057 14065
103. M Moon, HG Kim, L Hwang, JH Seo, S Kim, S Hwang, and et al. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation Neurotox Res 15 2009 332 347
104. JA Bayliss, and ZB Andrews Ghrelin is neuroprotective in Parkinson's disease: Molecular mechanisms of metabolic neuroprotection Ther Adv Endocrinol Metab 4 2013 25 36
105. AH Schapira, CW Olanow, JT Greenamyre, and E Bezard Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: Future therapeutic perspectives Lancet 384 2014 545 555
106. Y Xu, C Liu, S Chen, Y Ye, M Guo, Q Ren, and et al. Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease Cell Signal 26 2014 1680 1689
107. KC Choi, SH Kim, JY Ha, ST Kim, and JH Son A novel mTOR activating protein protects dopamine neurons against oxidative stress by repressing autophagy related cell death J Neurochem 112 2010 366 376
108. E Santini, M Heiman, P Greengard, E Valjent, and G Fisone Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia Sci Signal 2 2009 ra36
109. M Decressac, and A Björklund mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats J Parkinsons Dis 3 2013 13 17
110. C Malagelada, ZH Jin, V Jackson-Lewis, S Przedborski, and LA Greene Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease J Neurosci 30 2010 1166 1175
111. TF Jiang, YJ Zhang, HY Zhou, HM Wang, LP Tian, J Liu, and et al. Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy J NeuroImmune Pharmacol 8 1 2013 356 369
112. AK Mishra, MS ur Rasheed, S Shukla, MK Tripathi, A Dixit, and MP Singh Aberrant autophagy and parkinsonism: Does correction rescue from disease progression? Mol Neurobiol 51 2015 893 908
113. JC Koch, F Bitow, J Haack, Z d'Hedouville, JN Zhang, L Tönges, and et al. Alpha-synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons Cell Death Dis 6 2015 e1811
114. AM Cuervo, L Stefanis, R Fredenburg, P.T. Lansbury, and D. Sulzer Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy Science 305 2004 1292 1295
115. I Ahmed, Y Liang, S Schools, VL Dawson, TM Dawson, and JM Savitt Development and characterization of a new Parkinson's disease model resulting from impaired autophagy J Neurosci 32 2012 16503 16509
116. R Milo, and A Miller Revised diagnostic criteria of multiple sclerosis Autoimmun Rev 13 2014 518 524
117. R Milo, and E Kahana Multiple sclerosis: Geoepidemiology, genetics and the environment Autoimmun Rev 9 2010 A387 A394
118. R Dutta, and BD Trapp Pathogenesis of axonal and neuronal damage in multiple sclerosis Neurology 68 2007 S22 S31
119. BD Trapp, and KA Nave Multiple sclerosis: An immune or neurodegenerative disorder? Annu Rev Neurosci 31 2008 247 269
120. C Stadelmann, M Albert, C Wegner, and W Bruck Cortical pathology in multiple sclerosis Curr Opin Neurol 21 2008 229 234
121. SM Allan, PJ Tyrrell, and NJ Rothwell Interleukin-1 and neuronal injury Nat Rev Immunol 5 2005 629 640
122. R Hohlfeld Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives Brain 120 1997 865 916
123. JS Liu, ML Zhao, CF Brosnan, and SC Lee Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions Am J Pathol 158 2001 2057 2066
124. C Matute, E Alberdi, M Domercq, F Perez-Cerda, A Perez-Samartin, and MV Sanchez-Gomez The link between excitotoxicoligodendroglial death anddemyelinating diseases Trends Neurosci 24 2001 224 230
125. ZC Ye, MS Wyeth, S Baltan-Tekkok, and BR Ransom Functional hemichannelsin astrocytes: A novel mechanism of glutamate release J Neurosci 23 2003 3588 3596
126. I Micu, Q Jiang, E Coderre, A Ridsdale, L Zhang, J Woulfe, and et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia Nature 439 2006 988 992
127. AA Babcock, WA Kuziel, S Rivest, and T Owens Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS J Neurosci 23 2003 7922 7930
128. KL Munger, T Chitnis, and A Ascherio Body size and risk of MS in two cohorts of US women Neurology 73 2009 1543 1550
129. AK Hedström, T Olsson, and L Alfredsson High body index before age 20 is associated with increased risk for multiple sclerosis men and women Mult Scler J 18 2012 1334 1336
130. A Langer-gould, and BE Beaber Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome Neurology 80 2013 548 552
131. G Matarese, A Di Giacomo, V Sanna, GM Lord, JK Howard, A Di Tuoro, and et al. Requirement for leptin in the induction and progression of autoimmune encephalomyelitis J Immunol 166 2001 5909 5916
132. V Sanna, A Di Giacomo, A La Cava, RI Lechler, S Fontana, S Zappacosta, and et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses J Clin Invest 111 2003 241 250
133. V De Rosa, C Procaccini, A La Cava, P Chieffi, GF Nicoletti, S Fontana, and et al. Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis J Clin Invest 116 2006 447 455
134. M Galgani, C Procaccini, V De Rosa, F Carbone, P Chieffi, A La Cava, and et al. Leptin modulates the survival of autoreactive CD4 + T cells through the nutrient/energy-sensing mammalian target of rapamycinsignaling pathway J Immunol 185 2010 7474 7479
135. S Ouyang, H Hsuchou, AJ Kastin, PK Mishra, Y Wang, and W Pan Leukocyte infiltration into spinal cord of EAE mice is attenuated by removal of endothelial leptin signaling Brain Behav Immun 40 2014 61 73
136. G Frisullo, M Mirabella, F Angelucci, M Caggiula, R Morosetti, C Sancricca, and et al. The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis J Neuroimmunol 192 2007 174 183
137. C Lock, G Hermans, R Pedotti, A Brendolan, E Schadt, H Garren, and et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis Nat Med 8 2002 500 508
138. AP Batocchi, M Rotondi, M Caggiula, G Frisullo, F Odoardi, V Nociti, and et al. Leptin as marker of multiple sclerosis activity in patients treated with interferon-β J Neuroimmunol 139 2003 150 154
139. G Matarese, PB Carrieri, A La Cava, F Perna, V Sanna, V De Rosa, and et al. Leptin increase in multiple sclerosis associates with reduced number of CD4 + CD25 + regulatory T cells Proc Natl Acad Sci U S A 102 2005 5150 5155
140. MW Schwartz, and DG Baskin Leptin and the brain: Then and now J Clin Invest 123 2013 2344 2345
141. RS Ahima, C Bjorbaek, S Osei, and JS Flier Regulation of neuronal and glial proteins by leptin: Implications for brain development Endocrinology 140 1999 2755 2762
142. L Piccio, JL Stark, and AH Cross Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis J Leukoc Biol 8 2008 940 948
143. AI Esquifino, P Cano, V Jimenez, RA Cutrera, and DP Cardinali Experimental allergic encephalomyelitis in male Lewis rats subjected to calorie restriction J Physiol Biochem 60 2004 245 252
144. AI Esquifino, P Cano, V Jimenez-Ortega, MP Fernandez-Mateos, and DP Cardinali Immune response after experimental allergic encephalomyelitis in rats subjected to calorie restriction J Neuroinflammation 4 2007 6
145. VD Longo, and L Fontana Calorie restriction and cancer prevention: Metabolic and molecular mechanisms Trends Pharmacol Sci 31 2010 89 98
146. MM Theil, S Miyake, M Mizuno, C Tomi, JL Croxford, H Hosoda, and et al. Suppression of experimental autoimmune encephalomyelitis by ghrelin J Immunol 183 2009 2859 2866
147. A Penesova, M Vlcek, R Imrich, L Vernerova, A Marko, M Meskova, and et al. Hyperinsulinemia in newly diagnosed patients with multiple sclerosis Metab Brain Dis 30 2015 895 901
148. D Chesik, N Wilczak, and J De Keyser The insulin-like growth factor system in multiple sclerosis Int Rev Neurobiol 79 2007 203 226
149. D Bilbao, L Luciani, B Johannesson, A Piszczek, and N Rosenthal Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease EMBO Mol Med 6 2014 1423 1435
150. W Tan, Y Pu, Q Shao, X Fang, D Han, M Zhao, and et al. Insulin-like growth factor-binding protein 7 is up-regulated during EAE and inhibits the differentiation of oligodendrocyte precursor cells Biochem Biophys Res Commun 460 2015 639 644
151. N Wilczak, GS Ramsaransing, J Mostert, D Chesik, and J De Keyser Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis Mult Scler 11 2005 13 15
152. F Carbone, V De Rosa, PB Carrieri, S Montella, D Bruzzese, A Porcellini, and et al. Regulatory T cell proliferative potential is impaired in human autoimmune disease Nat Med 20 2014 69 74
153. M Esposito, F Ruffini, M Bellone, N Gagliani, M Battaglia, G Martino, and et al. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation J Neuroimmunol 220 2010 52 63
154. C Procaccini, V De Rosa, M Galgani, L Abanni, G CalI', A Porcellini, and et al. An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness Immunity 33 2010 929 941
155. GM Delgoffe, KN Pollizzi, AT Waickman, E Heikamp, DJ Meyers, MR Horton, and et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2 Nat Immunol 12 2011 295 303
156. C Li, E Capan, Y Zhao, J Zhao, D Stolz, SC Watkins, and et al. Autophagy is induced in CD4 + T cells and important for the growth factor-withdrawal cell death J Immunol 177 2006 5163 5168
157. HH Pua, I Dzhagalov, M Chuck, N Mizushima, and YW He A critical role for the autophagy gene Atg5 in T cell survival and proliferation J Exp Med 204 2007 25 31
158. HH Pua, and YW He Maintaining T lymphocyte homeostasis: Another duty of autophagy Autophagy 3 2007 266 267
159. T Hara, K Nakamura, M Matsui, A Yamamoto, Y Nakahara, R Suzuki-Migishima, and et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice Nature 441 2006 885 889
160. H Manev, M Favaron, A Guidotti, and E. Costa Delayed increase of Ca2 + influx elicited by glutamate: Role in neuronal death Mol Pharmacol 36 1989 106 112
161. D Mahad, I Ziabreva, H Lassmann, and D. Turnbull Mitochondrial defects in acute multiple sclerosis lesions Brain 131 2008 1722 1735
162. C Landles, and GP Bates Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series EMBO Rep 5 2004 958 963
163. NA Aziz, DF Swaab, H Pijl, and RA Roos Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: Clinical consequences and therapeutic implications Rev Neurosci 18 2007 223 251
164. N Taylor, and D Bramble Sleep disturbance and Huntingdon's disease Br J Psychiatry 17 1997 393
165. G Bates Huntingtin aggregation and toxicity in Huntington's disease Lancet 361 2003 1642 1644
166. E Cattaneo, D Rigamonti, D Goffredo, C Zuccato, F Squitieri, and S Sipione Loss of normal huntingtin function: new developments in Huntington's disease research Trends Neurosci 24 2001 182 188
167. M Gu, MT Gash, VM Mann, F Javoy-Agid, JM Cooper, and AH Schapira Mitochondrial defect in Huntington's disease caudate nucleus Ann Neurol 39 1996 385 389
168. MF Beal, NW Kowall, DW Ellison, MF Mazurek, KJ Swartz, and JB Martin Replication of the neurochemical characteristics of Huntington's disease by quinolinicacid Nature 321 1986 168 171
169. N Nakao, and P Brundin Effects of alpha-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatalinjections of quinolinate or 3-nitropropionic acid Neuroscience 76 1997 749 761
170. E Brouillet, P Hantraye, RJ Ferrante, R Dolan, A Leroy-Willig, NW Kowall, and et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates Proc Natl Acad Sci U S A 92 1995 7105 7109
171. C Portera-Cailliau, JC Hedreen, DL Price, and VE Koliatsos Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models J Neurosci 15 1995 3775 3787
172. TE Gunter, and DR Pfeiffer Mechanisms by which mitochondria transport calcium Am J Phys 258 1990 C755 C786
173. DR Green, and JC Reed Mitochondria and apoptosis Science 281 1998 1309 1312
174. IJ Reynolds, and TG Hastings Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation J Neurosci 15 1995 3318 3327
175. HP Kremer, and RA Roos Weight loss in Huntington's disease Arch Neurol 4 1992 349
176. N Wang, M Gray, XH Lu, JP Cantle, SM Holley, E Greiner, and et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease Nat Med 20 2014 536 541
177. AM Gaba, K Zhang, K Marder, CB Moskowitz, P Werner, and CN Boozer Energy balance in early-stage Huntington disease Am J Clin Nutr 81 2005 1335 1341
178. V Popovic, M Svetel, M Djurovic, S Petrovic, M Doknic, S Pekic, and et al. Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease Eur J Endocrinol 151 2004 451 455
179. RE Pratley, AD Salbe, E Ravussin, and JN Caviness Higher sedentary energy expenditure in patients with Huntington's disease Ann Neurol 47 2000 64 70
180. J Licinio, C Mantzoros, AB Negrao, G Cizza, ML Wong, PB Bongiorno, and et al. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function Nat Med 3 1997 575 579
181. L Djoussé, B Knowlton, LA Cupples, K Marder, I Shoulson, and RH Myers Weight loss in early stage of Huntington's disease Neurology 59 2002 1325 1330
182. A Petersén, and M Björkqvist Hypothalamic-endocrine aspects in Huntington's disease Eur J Neurosci 24 2006 961 967
183. LM Seoane, SA Tovar, D Perez, F Mallo, M Lopez, R Señaris, and et al. Orexin a suppresses in vivo GH secretion Eur J Endocrinol 150 2004 731 736
184. NA Aziz, H Pijl, M Frölich, JP Schröder-van der Elst, C van der Bent, F Roelfsema, and et al. Growth hormone and ghrelin secretion are associated with clinical severity in Huntington's disease Eur J Neurol 17 2010 280 288
185. R Zhang, G Yang, Q Wang, F Guo, and H Wang Acylated ghrelin protects hippocampal neurons in pilocarpine-induced seizures of immature rats by inhibiting cell apoptosis Mol Biol Rep 40 2013 51 58
186. I Ferrer, E Goutan, C Marín, MJ Rey, and T Ribalta Brain-derived neurotrophic factor in Huntington disease Brain Res 866 2000 257 261
187. JM Canals, JR Pineda, JF Torres-Peraza, M Bosch, R Martín-Ibañez, MT Muñoz, and et al. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease J Neurosci 24 2004 7727 7739
188. G Lynch, EA Kramar, CS Rex, Y Jia, D Chappas, CM Gall, and et al. Brain derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease J Neurosci 27 2007 4424 4434
189. TL Spires, HE Grote, NK Varshney, PM Cordery, A van Dellen, C Blakemore, and et al. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism J Neurosci 24 2004 2270 2276
190. NM Lalic, J Maric, M Svetel, A Jotic, E Stefanova, K Lalić, and et al. Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion Arch Neurol 65 2008 476 480
191. L Naia, M Ribeiro, J Rodrigues, AI Duarte, C Lopes, TR Rosenstock, and et al. Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin Neuropeptides 2016 [pii: S0143-4179(16)00017-2]
192. AI Duarte, GH Petit, S Ranganathan, JY Li, CR Oliveira, P Brundin, and et al. IGF-1 protects against diabetic features in an in vivo model of Huntington's disease Exp Neurol 231 2011 314 319
193. C Lopes, M Ribeiro, AI Duarte, S Humbert, F Saudou, L Pereira de Almeida, and et al. IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice Mol Neurobiol 49 2014 1126 1142
194. N Saleh, S Moutereau, JP Azulay, C Verny, C Simonin, C Tranchant, and et al. Huntington French speaking group. High insulinlike growth factor I is associated with cognitive decline in Huntington disease Neurology 75 2010 57 63
195. E Colin, E Regulier, V Perrin, A Durr, A Brice, P Aebischer, and et al. Akt is altered in an animal model of Huntington's disease and in patients Eur J Neurosci 21 2005 1478 1488
196. OA Andreassen, A Dedeoglu, V Stanojevic, DB Hughes, SE Browne, CA Leech, and et al. Huntington's disease of the endocrine pancreas: Insulin deficiency and diabetes mellitus due to impaired insulin gene expression Neurobiol Dis 11 2002 410 424
197. S Gines, E Ivanova, IS Seong, CA Saura, and ME MacDonald Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells J Biol Chem 278 2003 50514 50522
198. S Humbert, EA Bryson, FP Cordelieres, NC Connors, SR Datta, S Finkbeiner, and et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves huntingtin phosphorylation by Akt Dev Cell 2 2002 831 837
199. WM Pryor, M Biagioli, N Shahani, S Swarnkar, WC Huang, DT Page, and et al. Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington's disease Sci Signal 7 2014 ra103
200. JH Lee, L Tecedor, YH Chen, AM Monteys, MJ Sowada, LM Thompson, and et al. Reinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes Neuron 85 2015 303 315
201. YN Rui, Z Xu, B Patel, Z Chen, D Chen, A Tito, and et al. Huntingtin functions as a scaffold for selective macroautophagy Nat Cell Biol 17 2015 262 275
202. A Yamamoto, ML Cremona, and JE Rothman Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway J Cell Biol 172 2006 719 731
203. TC Frank-Cannon, LT Alto, FE McAlpine, and MG Tansey Does neuroinflammation an the flame in neurodegenerative diseases? Mol Neurodegener 4 2009 47
204. M Bjorkqvist, EJ Wild, J Thiele, A Silvestroni, R Andre, N Lahiri, and et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease J Exp Med 205 2008 1869 1877
205. S Hult, R Soylu, T Björklund, BF Belgardt, J Mauer, JC Brüning, and et al. Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits Cell Metab 13 2011 428 439
206. RJ Colman, RM Anderson, SC Johnson, EK Kastman, KJ Kosmatka, TM Beasley, and et al. Caloric restriction delays disease onset and mortality in rhesus monkeys Science 325 2009 201 204